Encompass Health (EHC) Could Be 11% Undervalued Following Strong Q3 Results

Encompass Health (EHC) drew fresh attention after third quarter 2026 results showed higher sales and net income than a year earlier, along with a small increase to full year revenue guidance.

Those results landed after a strong run in the share price, with Encompass Health now at $137.54 and a year to date share price return of 29.30%, alongside a 1 year total shareholder return of 20.20%. This has built on a very large 5 year total shareholder return, while recent capacity expansion plans in Texas and the Sea Pines closure update have kept attention on both growth projects and operational risks.

Scan beyond Encompass Health and line up other hospital and healthcare operators with resilient balance sheets using our curated list of solid balance sheet and fundamentals (25 results).

Encompass Health now looks like a powerful rehabilitation platform backed by solid recent results and fresh projects in Texas. After this share price run, are investors paying a fair price for that strength, or stretching for it?

Most Popular Narrative: 11% Undervalued

On the most followed narrative, Encompass Health screens as undervalued, with a fair value of $154.83 against the last close at $137.54, which puts the focus squarely on whether the current price fully reflects its rehab expansion story and recent execution.

Ongoing expansion of Encompass Health’s inpatient rehabilitation footprint through de novo hospitals, bed additions at high occupancy sites, and small format facilities, supported by a disclosed multi year pipeline and the reported returns on these projects, points to further discharge volume changes that can affect net operating revenue and EBITDA.

See why 7 investors see Encompass Health as 11% undervalued.

Result: Fair Value of $154.83 (UNDERVALUED)

Still, tighter Medicare Advantage behavior on authorizations and any less favorable Medicaid or tax decisions could quickly challenge the bullish Encompass Health narrative that investors are leaning on.

Find out about the key risks to this Encompass Health narrative.

Next Steps

That mix of optimism and concern around Encompass Health only matters if you weigh the evidence yourself and move before the narrative shifts. To see the full context of both the upside and the potential trouble spots, review the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Encompass Health?

Do not stop with Encompass Health. Use the Simply Wall Street Screener to spot fresh opportunities before the crowd starts paying attention to them.

• Target potential mispricing by scanning for companies that pair quality fundamentals with appealing valuations through the 36 high quality undervalued stocks.
• Prioritize resilience by reviewing a 31 resilient stocks with low risk scores that focuses on businesses with steadier risk scores and more robust financial profiles.
• Hunt for underfollowed opportunities by checking the 19 high quality undiscovered gems that filters for solid fundamentals where attention has been slower to arrive.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com